Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)

v3.21.2
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Series A Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) [1] 0 0
Series B Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) [2] 2,489,542 2,201,634
Series C Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) [3] 0 0
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 9,793,599 2,358,329
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 3,188,628 1,002,400
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 684,000 0
Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 232 249
[1] Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. As of June 30, 2020, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock.
[2] As of June 30, 2021 and 2020, a total of 38,090 and 33,685 shares of Series B convertible preferred stock were outstanding and convertible into 2,489,542 and 2,201,634 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.
[3] Each share of Series C preferred stock is convertible at any time at the holder's option into one share of common stock. As of June 30, 2021, all Series C convertible preferred stock had been converted into common stock and there are no remaining shares of Series C convertible preferred stock outstanding.